Investor Presentaiton
IBI-302 (VEGF/Complement) Development Plan Overview
First-in-class Bispecific Fusion Protein Blocking VEGF/Complement Proteins
•
•
.
IBI-302 Differentiated Advantages
High affinity blocker of VEGF family and complement protein that
simultaneously inhibits angiogenesis and inflammation pathways
IBI-302 is constructed by domains of human VEGFR1/2 and CR1 on the
human IgG1 backbone; Fully human sequence with low
immunogenicity risk
IBI-302 has the potential effect in retinal fibrosis and macular atrophy
Clinical Highlights
Primary outcomes of Phla in nAMD
Chang from baseline in BCVA
20
•
Clinical Highlights
Phase 1a data was published at 2020 AAO: good safety and tolerability
with promising effect
1) BCVA increased by 8 letters on average for 4mg group at week 12 and effect
lasts about 8~12 weeks after three loading injections
2) Average central retinal thickness decreased by 134μm at week 12
Phase 1b data will be disclosed at 2021 AAO
IBI-302 Development Program Overview
Neovascular/wet AMD
BCVA ETDRS letter
15
10
Day
8
15
29
43
Clinical
progress
Started Phase 2 trial in wet AMD in 2021.04
-0.05mg IBI302
-0.15mg IBI302
-0.5mg IBI302
1mg IBI302
2mg IBI302
2021 plan
•
4mg IBI302
Diabetic macular edema
BCVA: best corrected
visual acuity
Neovascular/Wet AMD
Phase 2 study exploring efficacy in fibrosis and macular
atrophy is underway in 40 sites
Phase 1b/2 trial in diabetic macular edema will be launched
by the end of 2021
Global first anti-VEGF/anti-complement bispecific molecule designed to potentially address huge unmet medical needs in neovascular AMD and
other ophthalmology diseases with poor response or declining effect under current anti-VEGF treatment. Good safety and tolerability, promising
Innovent
effect observed in Phase 1.
Confidential
Copyright©2021 Innovent Biologics
36View entire presentation